Stock Financial Ratios, Dividends, Split History

GM / General Motors Company financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price40.03
Volume8,806,100.00
Market Cap ($M)55,467.39
Enterprise Value ($M)42,653.24
Book Value ($M)34,298.00
Book Value / Share24.34
Price / Book1.62
NCAV ($M)-111,833.00
NCAV / Share-79.36
Price / NCAV-0.50
Share Statistics
Common Shares Outstanding 1,402,630,363
Weighted Average Number Of Diluted Shares Outstanding 1,492,000,000
Common Stock Shares Outstanding 1,400,000,000
Weighted Average Number Of Shares Outstanding Basic 1,465,000,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.11
Return on Assets (ROA)-0.02
Return on Equity (ROE)-0.09
Balance Sheet (mrq) ($M)
Assets218,726.00
Liabilities183,268.00
Quick Ratio0.73
Current Ratio0.86
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Sales Revenue Net0.00
Sales Revenue Net133,449,000,000.00
Disposal Group Including Discontinued Operation Financial Services Revenue0.00
Revenues145,588,000,000.00
Financial Services Revenue12,139,000,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Operating Income10,016.00
Net Income-3,882.00
Earnings Per Share Diluted-2.60
Earnings Per Share Basic-2.65
Cash Flow Statement (mra) ($M)
Cash From Operations17,328.00
Cash from Investing-27,572.00
Cash from Financing-27,572.00
Identifiers and Descriptors
CUSIP37045V100
Central Index Key (CIK)1467858
Related CUSIPS
30745V100 37045V900 370ESC774 370442105 37045V951 37045V950 370ESC766 37045V105 370ESC717 370ESC121 037045V10

Split History

Stock splits are used by General Motors Company to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

5 Top ROE Picks as Q2 Earnings Start on a Solid Note

1h zacks
The earnings season has kick started on a positive note with decent performance across the table. It appears that the equity markets have more or less factored in the risks from the ongoing trade war and is likely to have a relatively smooth spell, buoyed by improving economic sentiments led by solid domestic job market conditions, higher wage rates and lower taxes. As investors employ a wait-and-see approach in a classic example of “backing and filling” in the market, they could benefit from ‘cash cow’ stocks that garner higher returns. (30-0)

Tesla Fires A Shot Across The Bow

1h seekingalpha
Tesla Model S cars entered the market successfully, garnering sales from high-end BMW, Mercedes, Audi, Lexus, Cadillac, Jaguar customers. (75-0)

General Motors: Not Really An American Car Company Anymore

16h seekingalpha
It is fairly safe in terms of the trade war there as most of their sales come from joint ventures and are manufactured there, exempting them from tariffs. (14-0)

EU will reportedly talk with Trump to reduce auto tariffs, GM rises

19h cnbc
U.S. President Donald Trump and European Commission President Jean-Claude Juncker will meet next week to discuss a possible reduction of auto tariffs for several key trade partners, Bloomberg News reported Tuesday. Shares of General Motors and other automakers rose on the report. (14-0)

7 Top S&P 500 Stocks to Consider for Long-Term Gains | InvestorPlace

19h investorplace
The S&P 500 is an index containing the largest stocks in the country. Investors use it to gauge how stocks are doing overall, as it serves as a snapshot for the U.S. equities market. Generally speaking, the index is also used as a benchmark, as everyone from retail investors to hedge fund managers compare their performance to it. (49-2)

CUSIP: 37045V100